|
Neihu, Taiwan (August 12, 2020)
Abnova announced today that it continues to build COVID-19 sales momentum and gains a new 200K order for its EUA approved viral extraction kit from the US. The reopening from the COVID-19 pandemic has resulted in an escalation of transmission and death in the US. The demand is driving the climbing sales of its COVID-19 related products, particular the viral extraction kit. This new 200K is a third sales order and largest single order so far; the first and second orders were 100K each. Abnova plans to continue to ship out these orders in the coming months. First 100K order has been successfully shipped out last month.
Viral RNA extraction is a required sample preparation procedure before the gold standard COVID-19 RT-PCR nucleic acid test. Typical viral RNA extraction can be done manually or by automation. When the COVID-19 RT-PCR testing ramps out, it is critical to switch over to the automation to ensure processing throughput and testing quality. Abnova has provided a Precipitor® 32 magnetic beads automation to help the customer achieve these goals. Abnova expects the order to continue given the COVID-19 status in the US. Majority of the COVID-19 viral testing in the US is being performed in the clinical laboratories. |
+886-2-87511888
sales@abnova.com
Abnova has established a comprehensive portfolio of fully integrated solutions to address the needs of the in vitro diagnostic (IVD) industry. Abnova provides its partners and customers access to the technologies, products, and services relating to circulating rare cells, circulating exosomes, and circulating cell-free RNA for early to metastatic to recurrent disease and treatment diagnosis, prediction, guidance, and monitoring. Abnova facility is for proprietary bioreagent and high-throughput automation development and manufacturing for clinical trials and IVD commercialization. (www.abnova.com)